Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (241-250 of 293) with videos related to

Pageof 30
Sort By:
The Oncologist|March 15, 2012
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumorsRonan J Kelly, Robert W Robey, Clara C Chen, et al.
Leukemia & Lymphoma|August 11, 2025
Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphomaEmily R Gordon, Seda Tolu, Brigit A Lapolla, et al.
Frontiers in Pharmacology|September 1, 2015
Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasisNaheed Fatima, Devin C Cohen, Gauthaman Sukumar, et al.
The Oncologist|May 31, 2025
A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgeryRuth A White, Valeria Mezzano-Robinson, Qiongyu Shi, et al.
Seminars in Oncology|March 14, 2021
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in VeteransKeith Sigel, Mengxi Zhou, Yeun-Hee Anna Park, et al.
Molecular Cancer Research : MCR|May 29, 2021
R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor RomidepsinMaryam Safari, Thomas Litman, Robert W Robey, et al.
Cancer Letters|March 9, 2018
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivoGuan-Nan Zhang, Yun-Kai Zhang, Yi-Jun Wang, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinomaMaryam Safari, Luigi Scotto, Agnes Basseville, et al.
Molecular Cancer Therapeutics|June 10, 2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysLuigi Scotto, Cristina Kinahan, Eugene Douglass, et al.
Cancer Research|November 17, 2007
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistanceZhi Shi, Xing-Xiang Peng, In-Wha Kim, et al.
Pageof 30

Showing results (241-250 of 293) with videos related to

Sort By:
Pageof 30
The Oncologist|March 15, 2012
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumorsRonan J Kelly, Robert W Robey, Clara C Chen, et al.
Leukemia & Lymphoma|August 11, 2025
Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphomaEmily R Gordon, Seda Tolu, Brigit A Lapolla, et al.
Frontiers in Pharmacology|September 1, 2015
Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasisNaheed Fatima, Devin C Cohen, Gauthaman Sukumar, et al.
The Oncologist|May 31, 2025
A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgeryRuth A White, Valeria Mezzano-Robinson, Qiongyu Shi, et al.
Seminars in Oncology|March 14, 2021
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in VeteransKeith Sigel, Mengxi Zhou, Yeun-Hee Anna Park, et al.
Molecular Cancer Research : MCR|May 29, 2021
R-Loop-Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor RomidepsinMaryam Safari, Thomas Litman, Robert W Robey, et al.
Cancer Letters|March 9, 2018
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivoGuan-Nan Zhang, Yun-Kai Zhang, Yi-Jun Wang, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic adenocarcinomaMaryam Safari, Luigi Scotto, Agnes Basseville, et al.
Molecular Cancer Therapeutics|June 10, 2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysLuigi Scotto, Cristina Kinahan, Eugene Douglass, et al.
Cancer Research|November 17, 2007
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistanceZhi Shi, Xing-Xiang Peng, In-Wha Kim, et al.
Pageof 30